Evolution of incipient nephropathy in type 2 diabetes mellitus - Wikidata - wikimedia - TriplyDB

Evolution of incipient nephropathy in type 2 diabetes mellitus

Evolution of incipient nephropathy in type 2 diabetes mellitus

http://www.wikidata.org/entity/Q28145309

about

Influence of glucosamine on glomerular mesangial cell turnover: implications for hyperglycemia and hexosamine pathway flux Microalbuminuria in diabetes mellitus.Association of variants in the carnosine peptidase 1 gene (CNDP1) with diabetic nephropathy in American Indians.Podocyte detachment in type 2 diabetic nephropathy.Podocyte structural parameters do not predict progression to diabetic nephropathy in normoalbuminuric type 1 diabetic patients.Diet-Induced Podocyte Dysfunction in Drosophila and Mammals.Urinary excretion of viable podocytes in health and renal disease.Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy.Diabetic nephropathy in American Indians, with a special emphasis on the Pima Indians.Research into the glomerular podocyte--is it relevant to diabetic nephropathy?Improving outcomes in diabetes and chronic kidney disease: the basis for Canadian guidelines Dipstick urinalysis for diabetes screening in TB patients.Effect of losartan on prevention and progression of early diabetic nephropathy in American Indians with type 2 diabetes.Temporal profile of diabetic nephropathy pathologic changes.Pathophysiology of the diabetic kidney.Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis.Ras activation modulates methylglyoxal-induced mesangial cell apoptosis through superoxide production.Association between urinary IgG and relative risk for factors affecting proteinuria in type 2 diabetic patients.Xanthine Oxidase Activity in Type 2 Diabetes Mellitus Patients with and without Diabetic Peripheral Neuropathy.Diabetic kidney disease.A molecular morphometric approach to diabetic kidney disease can link structure to function and outcome.Modeling GFR trajectories in diabetic nephropathy.DW1029M, a novel botanical drug candidate, inhibits advanced glycation end-product formation, rat lens aldose reductase activity, and TGF-β1 signaling.Pharmacokinetics and Safety of DW1029M, a Botanical Drug for the Treatment of Diabetic Nephropathy, Following Single Doses in Healthy Subjects.Variants in the gene encoding aldose reductase (AKR1B1) and diabetic nephropathy in American Indians

P2860

Q33655472-5167CAEF-D170-4231-BB95-494CF89227D6 Q34004759-A42D723F-B986-4F63-B9ED-18FED485551C Q35004388-D27A33BC-B9A9-445A-B317-5D9881D2FE9A Q35063584-AA75E726-4047-4C1D-B5C2-A3E011A80ECE Q35888006-65F10A69-4633-4DCB-BC60-783C8677467A Q35941157-3FA08582-BA50-4922-BA58-3E651A8B3779 Q36012253-427248B1-23A9-490C-8631-B743BC96D80F Q36319830-7F76BA78-EBEC-4BBF-AD76-49DD3DF779C1 Q36345206-96735193-C43F-4A84-B057-55B3285BCF95 Q36536737-D170C5C9-5522-44A9-AA62-A55436D22E48 Q36834059-ADC5A8A6-87AE-4175-ACB0-ABA5D1AF9840 Q36921393-AE8124B7-DBE9-45E9-8718-E8A01F29C402 Q37110523-651771FC-C72C-40E9-A01B-4071D2515A7B Q38109847-34699600-0420-4C07-912E-4FC7D9112CBE Q38111707-27F8E514-97BB-462A-8D0D-98AF804540A6 Q38654795-D17F71E8-E77A-40CA-9751-913BDC71CC49 Q40053888-2A022D51-1E31-4E07-9117-528D353FD373 Q42057634-C15D8F9A-7BD9-4048-8C99-2A6E4BD78C27 Q42363114-45D9D782-BAE4-4F09-BEB1-55B55A2E9A79 Q43721013-9833E477-E511-42EA-8331-C3965A6C6C5A Q45972129-3FB35180-725A-48E8-8763-3773C96F89A1 Q46495855-D967FAD6-666D-482F-9660-DD50002F470C Q46910833-FDB42E72-2D0C-46EB-AD31-D55126384BAE Q50795437-4D8E5CC1-1B9D-4668-8810-1D99E67E9D45 Q59150529-2899DE06-D587-43DD-8A53-E965079F07D9

P2860

Evolution of incipient nephropathy in type 2 diabetes mellitus

http://www.wikidata.org/entity/Q28145309

description

2000 nî lūn-bûn

@nan

2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年論文

@yue

2000年論文

@zh-hant

2000年論文

@zh-hk

2000年論文

@zh-mo

2000年論文

@zh-tw

2000年论文

@wuu

name

Evolution of incipient nephropathy in type 2 diabetes mellitus

@ast

Evolution of incipient nephropathy in type 2 diabetes mellitus

@en

Evolution of incipient nephropathy in type 2 diabetes mellitus

@nl

type

label

Evolution of incipient nephropathy in type 2 diabetes mellitus

@ast

Evolution of incipient nephropathy in type 2 diabetes mellitus

@en

Evolution of incipient nephropathy in type 2 diabetes mellitus

@nl

prefLabel

Evolution of incipient nephropathy in type 2 diabetes mellitus

@ast

Evolution of incipient nephropathy in type 2 diabetes mellitus

@en

Evolution of incipient nephropathy in type 2 diabetes mellitus

@nl

P1433

Q28145309-C0624AC6-94B4-4B18-A72B-AA8A310A5597

P1476

Q28145309-0087443E-89A8-4749-A441-0EE835268C0F

P2093

Q28145309-0A1ABC21-26E9-4C38-BE67-18A37FA9B578

Q28145309-1FA69814-883A-4A43-8222-306E386B2F65

Q28145309-24FF7DF1-7F1C-4F54-A4C6-2B90BC4220A2

Q28145309-2544EC05-E39E-485C-91E5-7A7EFE46D5E5

Q28145309-3F00E5D8-D737-4339-A603-B981C4A7F241

Q28145309-82034965-A2B0-4A7E-9BE3-935D44B9932D

Q28145309-8940DB8B-A4CC-49E1-9CB9-EC14C73D34D8

Q28145309-E36543B9-39B2-46C1-9B0D-47460E9DD0E1

P2888

Q28145309-56B29EB2-F6EA-48CA-8F85-2F78AAEB1E07

P304

Q28145309-AD1A7931-D969-4E30-9183-71334D0EA487

P31

Q28145309-0DD05874-95EE-446F-A846-CC1DCA84D2DA

P356

Q28145309-379A744F-F50A-47E1-BBE4-5496460CB46F

P407

Q28145309-5C72CF43-DCBC-4BE3-9DB4-4C6334EF4630

P433

Q28145309-F6F95A09-F7F7-4053-9CEA-21EE5952BD72

P478

Q28145309-1134DFBC-1B30-4BEE-B791-105BB5780CCE

P577

Q28145309-CF1C5538-669D-413E-8D01-7F813EC650E3

P5875

Q28145309-0BF25E1A-71D6-4A14-9053-E9C16FDA64BC

P6179

Q28145309-A0E12222-E68B-4765-B794-BAC235B2CB75

P698

Q28145309-3BAC903F-84CA-43AF-B6F7-BC0DCDBAEA98

P921

Q28145309-56857BC0-929C-47A6-90C0-A8A98A30F656

P356

J.1523-1755.2000.00223.X

P1433

Kidney International

P1476

Evolution of incipient nephropathy in type 2 diabetes mellitus

@en

P2093

B D Myers

http://www.w3.org/2001/XMLSchema#string

I Abdullah

http://www.w3.org/2001/XMLSchema#string

K Blouch

http://www.w3.org/2001/XMLSchema#string

K V Lemley

http://www.w3.org/2001/XMLSchema#string

P H Bennett

http://www.w3.org/2001/XMLSchema#string

R G Nelson

http://www.w3.org/2001/XMLSchema#string

T W Meyer

http://www.w3.org/2001/XMLSchema#string

W E Smith

http://www.w3.org/2001/XMLSchema#string

P2888

j.1523-1755.2000.00223.x

P304

1228-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1046/J.1523-1755.2000.00223.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2000-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12348824

http://www.w3.org/2001/XMLSchema#string

P6179

1047905388

http://www.w3.org/2001/XMLSchema#string

P698

10972685

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes